- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced May 21, 2026, 11:58 PM EDT